These cancers exhibit sensitivities to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib or erlotinib, supporting the use of these drugs for effective treatment of NSCLC [5], [8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.